SB747651A-PEG3-pomalidomide

Target: SB747651A-PEG3-pomalidomide is designed to recruit MSK1 kinase to cereblon.

Binding site: Its kinase ligand occupies the ATP-competitive binding site of MSK1.

Mechanism of action: SB747651A-PEG3-pomalidomide is a CRBN-recruiting MSK1-directed PROTAC scaffold incorporating SB-747651A, a PEG3 linker, and pomalidomide. The longer PEG3 spacer is designed to alter ternary-complex geometry relative to PEG1 analogs, potentially improving or reducing productive alignment between MSK1 and CRL4CRBN. This molecule is valuable for degrader optimization studies examining linker length, target engagement, cellular permeability, degradation kinetics, and E3-dependent kinase turnover. It should be treated primarily as a research scaffold for evaluating MSK1 degradation feasibility rather than as a broadly validated degrader.

• PROTAC-Enhanced Drug Discovery: SB747651A-PEG3-pomalidomide facilitates the identification of novel therapeutic targets by enabling the selective degradation of disease-relevant proteins. This approach aids in elucidating protein function and assessing the therapeutic potential of previously undruggable targets, thereby advancing drug discovery efforts in various disease models.

• Targeted Degradation of Oncoproteins: By leveraging SB747651A-PEG3-pomalidomide, researchers can achieve specific degradation of oncogenic proteins, providing insights into cancer biology and potential therapeutic strategies. This targeted approach helps in dissecting the role of oncoproteins in tumorigenesis and validating them as viable targets for cancer treatment.

• Mechanistic Studies in Protein Homeostasis: Utilizing SB747651A-PEG3-pomalidomide allows for detailed mechanistic studies of protein turnover and homeostasis. Researchers can investigate the dynamics of protein degradation pathways, offering valuable data on cellular processes and the role of specific proteins in maintaining cellular health.

• Advancing Neurodegenerative Research: SB747651A-PEG3-pomalidomide aids in the study of neurodegenerative diseases by promoting the degradation of pathogenic proteins implicated in disorders like Alzheimer's and Parkinson's. This targeted degradation strategy provides a powerful tool for understanding disease mechanisms and exploring potential therapeutic interventions.